COVID-19 False Advertising Wasn't Any Falser Than During Other Public Health Crises; The Internet Was The Difference Maker
Executive Summary
The types of unsupported claims made during the COVID-19 pandemic have not been so different from those seen before when the US faced public health emergencies. But this time advertisers' digital capabilities turned up the volume on false and unsubstantiated claims about COVID cures and the like, says Rich Cleland, FTC Consumer Protection Bureau attorney.
You may also be interested in...
Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use
CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.
Xlear Admits Referencing Research, Avers Studies Support Saline Nasal Spray’s COVID-19 Efficacy
Firm responds to a complaint DoJ filed for FTC. Founder and president Nathan Jones continues criticism that FTC is attempting to silence research-backed advertising for alternatives to pharmaceuticals public health agencies promote for preventing or treating COVID-19.
COVID-19 False Advertising Symptoms In US Exceed FTC’s Prognosis For Number, Variety
FTC Division of Advertising Practices anticipated surge of false ads for consumer health products related to COVID-19 but it didn’t expect quite the number as well as the variety of bogus claims it’s found, says Assistant Director Richard Cleland.